Bio-Rad Laboratories reported robust financial results with a market capitalization of $7.67 billion and revenue of $2.59 billion, showcasing its resilience in the Medical Equipment and Supplies sector. The company’s earnings per share reached $27.91, complemented by a gross margin of 51.83% and a net margin of 6.52%. With a P/E ratio of 10.27 and a stable debt to equity ratio of 17.56%, Bio-Rad’s sales saw a slight increase of 0.65% over the past year, while its stock trades within a 52-week range of $211.43 to $343.12.
“Bio Rad Laboratories · has market cap · market cap · 7.674B”
“Bio Rad Laboratories · has shares outstanding · shares out · 26.76M”
“Bio Rad Laboratories · has 10 day average volume · 10 day average volume · 0.49M”
“Bio Rad Laboratories · has PE ratio (TTM) · P/E (TTM) · 10.27”
“Bio Rad Laboratories · has revenue · revenue · 2.59B”
“Bio Rad Laboratories · has gross margin · gross margin · 51.83%”
“Bio Rad Laboratories · has net margin · net margin · 6.52%”
“Bio Rad Laboratories · has debt to equity ratio · debt to equity · 17.56%”
“Bio Rad Laboratories · has 52 week high · 52 week high · 343.12”
“Bio Rad Laboratories · has 52 week low · 52 week low · 211.43”
“Bio Rad Laboratories · has EBITDA · EBITDA (TTM) · 411.50M”
“Bio Rad Laboratories · has EPS · EPS (TTM) · 27.91”